drugset / Trial / NCT04791319
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
Timeline
- Start
- 2021-05-03
- Primary completion
- 2022-02-02
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bermekimab | Monoclonal antibody | — | Subcutaneous |
| Comparator | Dupilumab | Monoclonal antibody | — | Subcutaneous |